@article{3943eaf69e85442ea8a2962880b21140,
title = "Ibrutinib induces durable remissions in treatment-na{\"i}ve patients with CLL and 17p deletion and/or TP53 mutations",
author = "Mariela Sivina and Ekaterina Kim and Wierda, {William G.} and Alessandra Ferrajoli and Nitin Jain and Philip Thompson and Hagop Kantarjian and Michael Keating and Burger, {Jan A.}",
note = "Funding Information: The authors thank the patients who participated in this trial and their families, the study investigators, and the study coordinator (Thomas Mathew) at the MD Anderson Cancer Center. This work was supported by Pharmacyclics (an AbbVie company), philanthropic contributions to The University of Texas MD Anderson Cancer Center Moon Shots Program, the CLL Global Research Foundation, and, in part, by a grant from the National Institutes of Health, National Cancer Institute (CA016672). Funding Information: Conflict-of-interest disclosure: J.A.B., N.J., and P.T. received research funding from Pharmacyclics and served as consultants for Janssen Pharmaceuticals. N.J. and P.T. have served as consultants for AbbVie, and N.J. has served as a consultant for Pharmacyclics. P.T. received funding from AbbVie. The remaining authors declare no competing financial interests. Funding Information: This work was supported by Pharmacyclics (an AbbVie company), philanthropic contributions to The University of Texas MD Anderson Cancer Center Moon Shots Program, the CLL Global Research Foundation, and, in part, by a grant from the National Institutes of Health, National Cancer Institute (CA016672). ",
year = "2021",
month = dec,
day = "16",
doi = "10.1182/blood.2021012315",
language = "English (US)",
volume = "138",
pages = "2589--2592",
journal = "Blood",
issn = "0006-4971",
publisher = "Elsevier B.V.",
number = "24",
}